🔎 Trials Near Me

Beranda › Kanker Paru › Illinois › Cicero

Uji klinis Kanker Paru di Cicero, IL

17 studi untuk Kanker Paru mencari peserta di lokasi sekitar Cicero (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Menerima pesertaFase 3
  • Edward Hines Jr VA Hospital, Hines · 4 mi jauhnya
  • Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04267848

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • OSF Little Company of Mary Medical Center, Evergreen Park · 9 mi jauhnya
  • Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Menerima pesertaFase 3
  • Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
Usia 70 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Menerima pesertaFase 3
  • Northwestern Medicine Oak Brook, Oak Brook · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT04181060

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Menerima pesertaFase 3
  • Northwestern Medicine Oak Brook, Oak Brook · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06498635

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Menerima pesertaFase 2
  • Hope and Healing Clinical Research, Hinsdale · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07476287

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Hope and Healing Cancer Services, Hinsdale · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07222566

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Menerima pesertaFase 2
  • Hope and Healing Clinical Research, Hinsdale · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07489066

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Menerima pesertaFase 3
  • Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
  • Hope and Healing Cancer Services, Hinsdale · 10 mi jauhnya
  • Endeavor Health, Elmhurst · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06758401

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
  • Advocate High Tech Medical Park, Palos Heights · 12 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05624996

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • Rush MD Anderson Cancer Center at Rush Oak Park, Oak Park · 3 mi jauhnya
  • Edward Hines Jr VA Hospital, Hines · 4 mi jauhnya
  • Loyola University Medical Center, Maywood · 5 mi jauhnya
  • dan 2 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572

MYLUNG Consortium Part 3: Observational Study

Menerima pesertaStudi observasional
  • Affiliated Oncologists, LLC, Chicago Ridge · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT05885698

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • Edward Hines Jr VA Hospital, Hines · 4 mi jauhnya
  • Loyola University Medical Center, Maywood · 5 mi jauhnya
  • Northwestern Medicine Oak Brook, Oak Brook · 9 mi jauhnya
18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2/3
  • Loyola University Medical Center, Maywood · 5 mi jauhnya
  • Northwestern Medicine Oak Brook, Oak Brook · 9 mi jauhnya
  • Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
  • dan 2 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06616584

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

Menerima peserta
  • Edward Hines Jr. VA Hospital, Hines, IL, Hines · 4 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Feb 2026 · NCT02984761

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

Menerima pesertaStudi observasional
  • Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
  • Advocate Outpatient Center - Oak Lawn, Oak Lawn · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jan 2026 · NCT06073431

Uji klinis Kanker Paru di kota lain

Studi lain di Cicero

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.